Contract Option Exercises — June 23, 2026

Analogic's competitive win for full-sized CT systems under full-and-open competition signals strong market position in airport security, with a long-dated 11-year performance period through 2033 providing revenue visibility.

Only $2.8 million of the $141.3 million contract has been outlayed, indicating milestone-based payments and high execution risk for a small, foreign-owned disadvantaged business in biotechnology R&D.

The $121.5 million cost-plus-fixed-fee order runs through August 2024, providing stable but capped margins; the $30.4M annual revenue is small relative to Leidos' overall revenue, making it a modest contributor.

START2 Group's $141.3M BARDA contract has only 2% outlayed ($2.8M), signaling early-stage biotechnology R&D with high technical and milestone risk for a small, foreign-owned disadvantaged business.

No single recipient or agency dominates, but HHS accounts for $262.8M (66%) of total obligation via BARDA and NIH contracts, creating civilian budget dependency.

Analogic Corp's $138.3M TSA order could face option exercise delays if airport security budgets are paused under a CR or sequestration scenario, given procurement is mid-cycle (awarded 2022).

Leidos' $121.5M NIH contract expires August 2024; re-compete could attract bidders due to stable NIH funding, and loss would remove $30.4M annual revenue for Leidos.

Analogic Corp's competitive TSA win positions it for additional DHS/TSA CT system orders as airports upgrade security infrastructure, with $361.4M in remaining options up to 2033.

START2 Group's $141.3M BARDA contract for biotechnology R&D could be a growth catalyst if milestone payments accelerate, given BARDA's sustained funding for biodefense under stable HHS budget trends.

Leidos' NIH contract renewal or follow-on award post-August 2024 could provide continued $30.4M annual revenue, given the stable NIH budget for vaccine research (NIAID VRC focus).

HHS awarded $262.8M (66% of total) for biotechnology and health R&D via BARDA and NIH, reflecting sustained government priority on biodefense and cancer research regardless of defense budget cycles.

Analogic Corp's $138.3M TSA award for full-sized CT systems, with a $499.7M potential ceiling, underscores multi-year federal investment in advanced screening technologies at U.S. airports.

{"entity"=>"Analogic Corp", "reason"=>"TSA CT system contract options worth up to $361.4M remain unexercised, representing significant revenue upside if exercised.", "trigger"=>"TSA option exercise announcement or DHS budget approval for airport security upgrades"}

{"entity"=>"START2 GROUP, INC.", "reason"=>"Only $2.8M of $141.3M BARDA contract outlayed; milestone progress is critical for revenue recognition and investor confidence.", "trigger"=>"Quarterly outlayed amount increase or BARDA milestone payment press release"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"$121.5M NIH contract expires August 2024; re-compete outcome will determine retention of $30.4M annual revenue stream.", "trigger"=>"NIH solicitation or award announcement for follow-on contract"}